Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Journal of Colloid and Interface Science|November 13, 2003
Protein adsorption: kinetics and history dependenceYanrong Tie, Claudio Calonder, Paul R Van TasselJournal of Biomedical Materials Research. Part A|August 2, 2005
Adsorbed layers of oriented fibronectin: a strategy to control cell-surface interactionsClaudio Calonder, Howard W T Matthew, Paul R Van TasselProteomics. Clinical Applications|December 8, 2010
Tracing pathway activities with kinase inhibitors and reverse phase protein arraysJan van Oostrum, Claudio Calonder, Daniel Rechsteiner, et al.Reproductive Toxicology (Elmsford, N.Y.)|November 8, 2019
"Simulect" as a model compound for assessing placental transfer of monoclonal antibodies in minipigsAdam Hey, Marilyn Hill, Claudio Calonder, et al.Clinical and Translational Science|July 13, 2026
Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous UrticariaYan Ji, Claudio Calonder, Tiina Kirsiläe, et al.The AAPS Journal|December 7, 2013
Automation practices in large molecule bioanalysis: recommendations from group L5 of the global bioanalytical consortiumAgo Ahene, Claudio Calonder, Scott Davis, et al.Clinical Pharmacology and Therapeutics|June 23, 2019
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe PsoriasisGerard Bruin, Anke Hasselberg, Irina Koroleva, et al.Mabs|May 8, 2026
A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in humanMonika Gajewska, Michael Kiffe, Claudio Calonder, et al.Pharmaceutics|September 28, 2023
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery SystemYan Ji, Claudio Calonder, Tiina Kirsilä, et al.RMD Open|February 23, 2025
Targeting the IL-17A pathway for therapy in early-stage tendinopathyNeal L Millar, Iain B McInnes, Frank Kolbinger, et al.Pageof 2